Effect of nonnicotine pharmacotherapy on smoking behavior.
Smoking-related disease is the single biggest preventable cause of morbidity and mortality in the United States, yet approximately 25% of Americans continue to smoke. Various dosage forms of nicotine replacement therapy increase smoking quit rates relative to placebo, but they generally do not result in 1-year quit rates of over 20%. To increase these rates, a number of nonnicotine agents have been investigated. Drugs that modulate noradrenergic neurotransmission (bupropion, nortriptyline, moclobemide) are more effective than those affecting serotonin (selective serotonin reuptake inhibitors, buspirone, ondansetron) or other neurotransmitters.
Kotlyar
M
M
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota at Twin Cities, Minneapolis 55455, USA.
Golding
M
M
Hatsukami
D K
DK
Jamerson
B D
BD
D000662:Amphetamines / Q000627:therapeutic use; D016642:Bupropion / Q000627:therapeutic use; D003000:Clonidine / Q000627:therapeutic use; D004316:Doxepin / Q000627:therapeutic use; D006801:Humans; D009271:Naltrexone / Q000627:therapeutic use; D009661:Nortriptyline / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D016540:Smoking Cessation / Q000379:methods*
D000662:Amphetamines; D016642:Bupropion; D003000:Clonidine; D004316:Doxepin; D009271:Naltrexone; D009661:Nortriptyline; D017367:Selective Serotonin Reuptake Inhibitors